• Total revenue of $88.1m, up 33% on FY25 ($66.1m)
• EBITDA of $27.2m, a 68% increase on FY25 ($16.1m)
• 24 new lease agreements signed in FY26, bringing total contracted units to 87

Chrysos Corporation Ltd (ASX:C79) reported record earnings and revenue for FY26, driven by increasing deployments and high utilisation of its PhotonAssayTM technology. The company achieved total revenue of $88.1 million, a 33% increase from FY25. EBITDA grew by 68% to $27.2 million, with an EBITDA margin of 31%. The company signed 24 new lease agreements during FY26, bringing the total contracted units to 87. Chrysos also deployed seven units during FY26 and had six units currently deploying. Sample volumes reached a new record of 1,000,000 samples per month for five consecutive months since March 2026. The company ended FY26 with a strong funding position, with $25.9 million in cash and $140 million in undrawn debt.

Chrysos expects FY27 revenue of $108m to $118m and EBITDA of $35m to $42m

Chrysos enters FY27 well-positioned with a larger contracted fleet, a maturing installed base, and a strengthened operating platform.